Product Profile

Bio-Techne expands RNAscope® Assay Services portfolio to shorten development times and save costs


io-Techne has added new capabili- ties and options to its Advanced Cell Diagnostics (ACD)-branded RNA-

scope® and BaseScope™ in situ hybridisa- tion (ISH) Assay Services Portfolio to improve biotech and pharma discovery timelines and costs. Responding to cus- tomer needs, the company has expanded its pre-validated tissue bank with new tissues and disease types and created pre-collected immuno-oncology datasets, profiling key targets and immune checkpoint markers. Biotech and pharma companies can great-

ly benefit from the reliable and reproducible gene expression analysis delivered by the RNAscope technology in the development of therapeutics, biomarkers and companion diagnostics. This high-quality RNA ISH assay overcomes many of the challenges of using antibodies and can be used in conjunc- tion with immunohistochemistry (IHC). In place of developing assays in-house,

which can be time-consuming, Bio-Techne’s ACD Assay Services provide rapid in situ gene expression analysis for target valida- tion, drug safety assessment and biomarker discovery directly from the technology experts. The services cover the entire work- flow, from RNA ISH probe validation to data analysis – with results delivered within four weeks on average. In addition, the ser-

blocks, human multi-tumour tissue microar- ray (TMA), normal human TMA, and mouse and rat multi-tissue TMAs with a 100% pass rate and confirmed RNA quali- ty. Pretreatment conditions have also been established for each sample, eliminating the need for optimisation. In addition, Bio-Techne has also begun

vices offer quantitative image analysis and data review by board-certified pathologists. The RNAscope and BaseScope assays can detect any mRNA and lncRNA molecule, as well as hard-to-detect splice variants in any tissue of any species. This facilitates pharma and biotech preclinical research in all thera- peutic areas and the development of com- panion diagnostics and clinical biomarkers, particularly in oncology. Bio-Techne’s expanded Assay Services tis-

sue bank resources – a set of high-quality, pre-sourced and pre-validated samples – now include new tissues and disease types. Access to the tissue bank eliminates the need to purchase tissues from a third party, which can otherwise take two to three weeks, and saves tissue processing, handling and QC validation time. Using pre-validated tissues also guarantees results, avoiding the risk of tissues of unknown quality. The tissue bank includes a collection of validated tissue

to produce pre-generated, ready-to-use tis- sue profiling datasets. The first of these is now available and looks at immuno-oncol- ogy checkpoint controls in non-squamous lung cell carcinoma (NSCLC). Access to such datasets greatly facilitates biomarker and therapeutic identification and develop- ment, saving significant time, resources, and costs by eliminating the need to create and perform various assays. Tom Olenic, Vice President & General

Co-expression of PD-L1 and IDO1 in lung cancer: Single-cell analysis by the RNAscope 2.5 HD Duplex Assay revealed co-expression of IDO1(Hs-IDO1; red) with PD-L1(Hs-CD274; green) in a lung cancer tumour core

Drug Discovery World Summer 2018

Manager of Advanced Cell Diagnostics, com- mented: “RNAscope and BaseScope assays are an invaluable tool for pharma and biotech companies. We wanted to make access to our technology even easier, which is why we created the Assay Services offering some years back. These enable us to run and develop assays for our customers, significant- ly reducing their discovery times and costs. We have listened to customer needs, expand- ing our tissue bank and creating readily avail- able datasets to enhance this even further. Our goal is to facilitate drug discovery and development as much as possible by always being responsive to customer feedback and requests, and by developing tools and services that really help to achieve research goals as quickly and as easily as possible.” Bio-Techne’s sensitive and specific RNAscope and BaseScope assays are used by more than 5,000 laboratories, including all the major pharma and biotech compa- nies, and are featured in more than 1,400 published research papers. The technology enables robust single RNA molecule detec- tion, even in formalin-fixed, paraffin- embedded (FFPE) tissues, overcoming the limitations of traditional ISH and many of the challenges of IHC. Please visit for more information.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80